Dostarlimab (Jemperli)
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for Dostarlimab (Jemperli), covering 2025-02-03 to 2026-02-02. Get the full timeline:
Most recent: Clinical Trial Update: XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients [Phase 2]